Argenx SE(ARGX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ARGX Argenx SE

盘后交易 11-04 17:39:44 EST

931.38

+30.26

+3.36%

盘后914.40

-16.98-1.82%

17:05 EST

最高933.39	最低895.49	成交量64.58万
今开922.71	昨收901.12	日振幅4.21%
总市值582.47亿	流通市值582.47亿	总股本6,254万
成交额5.92亿	换手率1.03%	流通股本6,254万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ARGX","market":"US","secType":"STK","nameCN":"Argenx SE","latestPrice":931.38,"timestamp":1793826000000,"preClose":901.12,"halted":0,"volume":645814,"hourTrading":{"tag":"盘后","latestPrice":914.4,"preClose":931.38,"latestTime":"17:05 EST","volume":2232,"amount":2078708.472,"timestamp":1793829958874,"change":-16.98,"changeRate":-0.018231,"amplitude":0.019015},"delay":0,"changeRate":0.033580433238636354,"floatShares":62537923,"shares":62537923,"eps":28.875658,"marketStatus":"盘后交易","change":30.26,"latestTime":"11-04 17:39:44 EST","open":922.71,"high":933.385,"low":895.49,"amount":592374764.3606,"amplitude":0.042053,"askPrice":935,"askSize":2,"bidPrice":913.22,"bidSize":2,"shortable":3,"etf":0,"ttmEps":28.875658,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1793840400000},"marketStatusCode":4,"adr":1,"adrRate":1,"listingDate":1495080000000,"exchange":"NASDAQ","adjPreClose":901.12,"preHourTrading":{"tag":"盘前","latestPrice":922.43,"preClose":901.12,"latestTime":"09:29 EST","volume":44260,"amount":40542487.524,"timestamp":1793802599119,"change":21.31,"changeRate":0.023648,"amplitude":0.024325},"postHourTrading":{"tag":"盘后","latestPrice":914.4,"preClose":931.38,"latestTime":"17:05 EST","volume":2232,"amount":2078708.472,"timestamp":1793829958874,"change":-16.98,"changeRate":-0.018231,"amplitude":0.019015},"volumeRatio":2.082936,"impliedVol":0.4252,"impliedVolPercentile":0.8008},"requestUrl":"/m/hq/s/ARGX","defaultTab":"news","newsList":[{"id":"1170051610","title":"异动解读｜Argenx SE盘中下跌3.11%，财报后市场聚焦盈利略低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1170051610","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170051610?lang=zh_cn&edition=full","pubTime":"2026-10-22 21:50","pubTimestamp":1792677000,"startTime":"0","endTime":"0","summary":"10月22日，Argenx SE盘中下跌3.11%，报884.83美元，成交额1.11亿美元。本次异动由财报落地后的业绩消化驱动。公司第三季度每股收益为7.80美元，低于市场预期的7.83美元；销售额为17.51亿美元，高于预期的16.64亿美元。市场此前对其核心产品增长与新适应症进展已有较高预期，且股价近期已受肌炎三期试验成功、干燥综合征项目终止及乳糜泻管线推进等消息扰动；在营收超预期背景下，盈利端小幅不及预期成为股价承压的直接触发因素。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Argenx财报后走低，盈利略逊预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182932183","title":"异动解读｜Argenx SE盘前下跌3.46%，财报发布后市场聚焦盈利略低于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1182932183","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182932183?lang=zh_cn&edition=full","pubTime":"2026-10-22 19:03","pubTimestamp":1792666983,"startTime":"0","endTime":"0","summary":"10月22日，Argenx SE盘前下跌3.46%，报856.34美元，成交额41.5万美元。本次异动由财报驱动。公司最新披露第三季度每股收益7.80美元，低于市场预期的7.83美元；但销售额17.51亿美元，高于预期的16.64亿美元。从背景看，市场此前对公司核心产品销售延续高增长抱有较高预期，且股价近期已受肌炎三期试验成功、干燥综合征项目终止及乳糜泻管线进展等多重研发消息扰动，财报落地后，盈利端小幅不及预期成为盘前承压的直接触发因素。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Argenx财报盈利略逊预期，盘前股价承压下行","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119690553","title":"异动解读｜Argenx SE夜盘下跌5.22%，财报前夕股价承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1119690553","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119690553?lang=zh_cn&edition=full","pubTime":"2026-10-22 13:01","pubTimestamp":1792645282,"startTime":"0","endTime":"0","summary":"10月22日，Argenx SE夜盘下跌5.22%，报843.6美元，成交额137.4万美元。本次异动更接近财报驱动。公司将于当日盘前披露新一季业绩，市场预期每股收益为7.44美元；此前机构提示，股价近期大幅波动主要受药物研发进展影响。背景上，公司8月公布Vyvgart Hytrulo治疗自身免疫性肌炎三期试验达主要终点，一度提振估值；但10月终止干燥综合征三期试验后股价承压。与此同时，FB102治疗乳糜泻Ⅱ期试验达到主要终点，被视为后续情绪修复的重要支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前夕夜盘承压，Argenx股价异动","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160329962","title":"异动解读｜Argenx SE盘中上涨5.75%，RBC称股价波动后乳糜泻突破或被低估","url":"https://stock-news.laohu8.com/highlight/detail?id=1160329962","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160329962?lang=zh_cn&edition=full","pubTime":"2026-10-21 00:13","pubTimestamp":1792512790,"startTime":"0","endTime":"0","summary":"10月21日，Argenx SE盘中上涨5.75%，报873.085美元，成交额2.49亿美元。最新消息面上，RBC指出，公司股价近期大幅波动主要受药物研发进展驱动，市场可能低估其在乳糜泻领域的突破，并维持跑赢大市观点。此前公司8月公布Vyvgart Hytrulo治疗自身免疫性肌炎三期研究达主要终点，一度提振股价；10月又终止干燥综合征三期试验，导致股价承压。与此同时，公司披露FB102治疗乳糜泻Ⅱ期试验达到主要终点，显示统计学显著且具临床意义疗效，成为当前情绪修复的重要支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Argenx股价大涨，乳糜泻突破受瞩目","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153651284","title":"异动解读｜Argenx SE盘中下跌3.02%，财报临近与前期临床扰动继续博弈","url":"https://stock-news.laohu8.com/highlight/detail?id=1153651284","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153651284?lang=zh_cn&edition=full","pubTime":"2026-10-16 23:07","pubTimestamp":1792163240,"startTime":"0","endTime":"0","summary":"10月16日，Argenx SE盘中下跌3.02%，报820.67美元，成交额8214.83万美元。消息面上，公司将于10月22日公布新一季财报，市场继续围绕核心产品Vyvgart销售动能与盈利弹性展开博弈。目前市场预期公司本季度营收同比增长58.46%，预期每股收益为7.44美元；上一季度公司营收15.41亿美元，同比增长59.33%，净利润4.72亿美元。此前公司终止Vyvgart用于干燥综合征的III期UNITY研究，虽未见新安全性信号，但临床扰动后股价仍对财报兑现度较为敏感。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动下跌，财报前临床扰动持续博弈","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144484434","title":"异动解读｜Argenx SE盘中上涨3.38%，财报临近叠加机构预期偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1144484434","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144484434?lang=zh_cn&edition=full","pubTime":"2026-10-15 21:51","pubTimestamp":1792072297,"startTime":"0","endTime":"0","summary":"10月15日，Argenx SE盘中上涨3.38%，报850.71美元，成交额5843.9万美元。此次异动的消息面，主要与公司将于10月22日公布新一季财报、市场对核心产品Vyvgart销售动能及盈利弹性的关注升温有关，机构整体观点偏多。市场预期显示，公司本季度营收同比预计增长58.46%，预期每股收益为7.44美元。上一季度公司营收15.41亿美元，同比增长59.33%，净利润4.72亿美元；在终止干燥综合征三期试验后，市场情绪已有所修复，财报前业绩预期成为股价支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报临近，Argenx盘中上涨引关注","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144769874","title":"异动解读｜Argenx SE盘前上涨3.26%，财报临近叠加机构预期偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1144769874","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144769874?lang=zh_cn&edition=full","pubTime":"2026-10-15 21:29","pubTimestamp":1792070983,"startTime":"0","endTime":"0","summary":"10月15日，Argenx SE盘前上涨3.26%，报843.81美元，成交额200.18万美元。此次异动的消息面，主要与公司将于10月22日公布新一季财报、市场对核心产品Vyvgart销售动能及盈利弹性的关注升温有关，机构整体观点偏多。市场预期显示，公司本季度营收同比预计增长58.46%。在此前终止干燥综合征三期试验后，市场情绪已出现修复，财报前的业绩预期成为股价反弹的重要支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Argenx财报在即，盘前异动拉升","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186084912","title":"财报前瞻 | Argenx SE本季度营收预计增58.46%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1186084912","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186084912?lang=zh_cn&edition=full","pubTime":"2026-10-15 08:32","pubTimestamp":1792024348,"startTime":"0","endTime":"0","summary":"Argenx SE将于2026年10月22日发布新一季财报，市场聚焦核心产品销售动能与盈利弹性变化。上季度公司营收为15.41亿美元，同比增长59.33%；毛利率为59.05%，归属于母公司股东的净利润为4.72亿美元，净利率为30.63%；调整后每股收益为7.33美元，同比增长95.99%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 | Argenx SE本季度营收预计增58.46%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119551228","title":"异动解读｜Argenx SE盘中上涨3.36%，终止干燥综合征三期试验后股价反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1119551228","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119551228?lang=zh_cn&edition=full","pubTime":"2026-10-15 00:13","pubTimestamp":1791994415,"startTime":"0","endTime":"0","summary":"10月15日，Argenx SE盘中上涨3.36%，报828.96美元，成交额1.76亿美元。近期公司消息面仍围绕Vyvgart适应症拓展调整。此前公司宣布，因独立数据监测委员会在中期分析中认定难以达成主要终点，终止efgartigimod皮下注射剂用于中重度干燥综合征的III期UNITY研究，但同时表示未发现新的安全性信号。另外，公司同期披露，收购而来的FB102在成人乳糜泻II期研究中达到主要终点，显示具统计学意义且具临床相关性的疗效，或为市场提供一定支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Argenx终止干燥综合征试验，股价反弹","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131123997","title":"异动解读｜Argenx SE盘中下跌13.53%，终止干燥综合征三期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1131123997","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131123997?lang=zh_cn&edition=full","pubTime":"2026-10-08 22:28","pubTimestamp":1791469708,"startTime":"0","endTime":"0","summary":"10月8日，Argenx SE盘中下跌13.53%，报803.07美元/股，成交额6.46亿美元。消息面上，公司宣布独立数据监测委员会建议停止efgartigimod皮下注射治疗中重度干燥综合征的三期研究，理由为无效性，研究未能达到主要终点。公司表示试验未出现新的安全性信号，efgartigimod SC耐受性与已知安全特征一致。Argenx SE是一家处于商业阶段的全球性生物制药公司，开发用于治疗严重自身免疫性疾病的差异化疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Argenx终止干燥综合征试验，股价重挫","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673079097","title":"argenx SE（ARGX）跌超14% Vyvgart干燥综合征III期试验终止","url":"https://stock-news.laohu8.com/highlight/detail?id=2673079097","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673079097?lang=zh_cn&edition=full","pubTime":"2026-10-08 19:03","pubTimestamp":1791457417,"startTime":"0","endTime":"0","summary":"金吾财讯 | argenx SE（ARGX）盘前股价承压，最新跌14.48%，报794美元。消息面上，荷兰生物科技公司Argenx宣布，终止重磅疗法Vyvgart注射剂型用于自身免疫疾病干燥综合征的后期临床试验。3期UNITY研究面向中重度干燥综合征成年患者，测试efgartigimod alfa皮下注射制剂，该制剂依托Halozyme（HALO）的Enhanze药物递送技术开发。独立数据监测委员会经中期分析判断，该研究难以达成主要终点，因此建议终止试验；公司表示试验未出现新的安全性信号，efgartigimod SC耐受性与已知安全特征保持一致。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/YjZmMjQ4YmQ4ZjZmMDRlNTI1MzFkZTUxNzM2MjM3NjU3NDA0.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YjZmMjQ4YmQ4ZjZmMDRlNTI1MzFkZTUxNzM2MjM3NjU3NDA0.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306975","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0889565916.HKD","IE00B4R5TH58.HKD","ARGX","LU2324357040.USD","BK4588","IE0002141913.USD","BK4505","IE00BJT1NW94.SGD","IBB","IE00BJJMRZ35.SGD","IE0009355771.USD","LU0320765992.SGD","BK4139","IE00BFTCPJ56.SGD","FMED","LU0390134368.USD","TBXU","IE0034235188.USD","LU1983260115.SGD","IE00B2B36J28.USD","BK4585","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136475651","title":"异动解读｜Argenx盘前跌超17%，终止干燥综合征三期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1136475651","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136475651?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:08","pubTimestamp":1791450506,"startTime":"0","endTime":"0","summary":"10月8日，Argenx盘前下跌17.57%，报768.00美元/股，成交额70.88万美元。消息面上，公司宣布独立数据监测委员会建议停止efgartigimod皮下注射治疗中重度干燥综合征的三期研究，理由为无效性，研究未能达到主要终点。此前Argenx以22亿美元收购Forte Biosciences获得FB102，此番数据虽积极，但未能扭转投资者对短期估值承压的担忧。Argenx SE是一家处于商业阶段的全球性生物制药公司，开发用于治疗严重自身免疫性疾病的差异化疗法。","market":"us","thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"三期试验终止，Argenx盘前大跌","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146034637","title":"异动解读｜Argenx SE盘中上涨3.06%，肌炎三期数据催化延续叠加机构上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1146034637","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146034637?lang=zh_cn&edition=full","pubTime":"2026-08-27 00:13","pubTimestamp":1787760797,"startTime":"0","endTime":"0","summary":"8月26日，Argenx SE盘中上涨3.06%，报1050.73美元/股，成交额1.5亿美元。消息面上，公司核心产品Vyvgart Hytrulo治疗自身免疫性肌炎的三期ALKIVIA试验此前达到主要终点，多家机构持续给予积极评价。Wedbush将目标价上调至1150美元，RBC、Morgan Stanley及Oppenheimer均认为该数据降低了Vyvgart约15至20亿美元肌炎市场机会的不确定性。公司二季度营收15.42亿美元超预期7%，EPS 7.32美元超预期17%，基本面持续强劲。此次上涨或为前一交易日回调后的修复性反弹。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Argenx肌炎数据催化，盘中强势上扬","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182552700","title":"异动解读｜Argenx SE盘前上涨3.85%，肌炎三期数据催化延续叠加机构上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1182552700","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182552700?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:41","pubTimestamp":1787740883,"startTime":"0","endTime":"0","summary":"8月26日，Argenx SE盘前上涨3.85%，报1058.75美元/股，成交额25.34万美元。多家机构对此给出积极评价，Wedbush将目标价上调至1150美元，RBC、Morgan Stanley及Oppenheimer均认为该数据降低了Vyvgart约15至20亿美元肌炎市场机会的不确定性。公司此前二季度营收15.42亿美元超预期7%，EPS 7.32美元超预期17%，基本面持续强劲。此次盘前上涨或为前一交易日回调后的修复性反弹。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"肌炎三期数据获机构力挺，Argenx盘前上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661427725","title":"Argenx（ARGX）股价走高遭评级下调 新药商业化预期成为博弈焦点","url":"https://stock-news.laohu8.com/highlight/detail?id=2661427725","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661427725?lang=zh_cn&edition=full","pubTime":"2026-08-24 23:18","pubTimestamp":1787584698,"startTime":"0","endTime":"0","summary":"同时机构重点关注在研药物empasiprubart用于罕见肌肉运动障碍多灶性运动神经病变的三期EMPASSION临床试验，虽然对试验结果保持乐观，但判断这条管线不确定性更高，情绪扰动会更大，不足以支撑当前股价位置继续进一步加仓。市场已经充分反应核心药物临床利好，新适应症带来增量有限，后期需要重点跟踪empasiprubart三期试验读出结果，该管线成败将会显著影响公司长期估值。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NjEzNTY0MzU5MDE2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NjEzNTY0MzU5MDE2.png"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305257","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FALN","ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152195298","title":"异动解读｜Argenx SE盘中上涨3.17%，多家投行上调评级确认肌炎数据利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1152195298","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152195298?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:45","pubTimestamp":1787147114,"startTime":"0","endTime":"0","summary":"8月19日，Argenx SE盘中上涨3.17%，报1025.73美元/股，成交额2985.1万美元。消息面上，公司核心药物efgartigimod治疗自身免疫性肌炎的三期ALKIVIA试验达到主要终点后，多家华尔街投行密集发布看多研报。Oppenheimer指出该数据降低了Vyvgart在肌炎领域15亿至20亿美元市场机会的不确定性；RBC Capital Markets认为Vyvgart Hytrulo获FDA批准的可能性较高；Morgan Stanley表示数据强化了efgartigimod整体前景并上调成功概率假设；Wedbush将目标价从1050美元上调至1150美元并维持跑赢大盘评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143114221","title":"异动解读｜Argenx SE夜盘下跌3.83%，报950.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143114221","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143114221?lang=zh_cn&edition=full","pubTime":"2026-08-18 15:01","pubTimestamp":1787036493,"startTime":"0","endTime":"0","summary":"8月18日，Argenx SE夜盘下跌3.83%，报950.02美元/股，成交额1.27万美元。Argenx SE所在的生物科技行业中，个股涨跌不一，其中安进涨0.39%，艾伯维公司涨0.04%，福泰制药涨0.75%，吉利德科学涨0.04%，Revolution Medicines跌0.03%。Argenx SE是一家处于商业阶段的全球性生物制药公司，专注于开发用于治疗严重自身免疫性疾病的差异化疗法。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137019504","title":"美股开盘 | 三大指数涨跌不一，闪迪涨超3%，Argenx SE涨近9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1137019504","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137019504?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:32","pubTimestamp":1786973544,"startTime":"0","endTime":"0","summary":"8月17日，美股三大指数开盘涨跌不一，道琼斯指数跌0.23%，标普500指数涨0.04%，纳斯达克综合指数涨0.24%。美股存储股普涨，SK海力士、西部数据、闪迪涨超3%，美光科技、希捷科技涨超2%。OmniAb涨超23%，公司此前宣布与礼来达成3.7亿美元药物研发协议。Argenx SE涨近9%，Efgartigimod治疗肌炎III期试验成功。","market":"us","thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MUZ","LU2106854487.HKD","LU1366333091.USD","LU1674673428.USD","LU1064131342.USD","LU2896262040.SGD","LU1868837300.USD","JGRO","FMED","LU1323610961.USD","IE00BFSS8Q28.SGD","SPY","LU1803068979.SGD","LU0127658192.USD","TMED","LU0203347892.USD","LU0823434583.USD","MUU","SNDK","EMSF","LU1988902786.USD","SGXZ81514606.USD","LU1712237335.SGD","WDCX","SG9999001176.SGD","CNEQ","SG9999018865.SGD","BK4585","LU1868836757.USD","BK4605","LU0353189763.USD","LU0320765992.SGD","BK4534","IE0002141913.USD","LU0385154629.USD","IE00BK4W5M84.HKD","MU","LU2462157665.USD","LU0471298694.HKD","LU0289739699.SGD","DIA","IE00B894F039.SGD","IE00B7KXQ091.USD","THNR","DDM","IE00BN29S564.USD","BK4579","LU2456880835.USD","LU1267930813.SGD","IE00B1BXHZ80.USD","LU1127390331.HKD","IE00BKPKM429.USD","RULE","IVV","ARGX","LU2108987350.USD","BK4141","TMSL","LU2112291526.USD","BK4532","LU1670627923.USD","LU0157215616.USD","AGNG","LU2237443622.USD","LU0787776722.HKD","LU0820562030.AUD","SNDC","FTEC","LU0354030511.USD","LU2250418816.HKD","LU0444973449.USD","LU2746668461.USD","BK4588","HBMX","SK","SPYU","LU1093756168.USD","LU0353189680.USD","LLII","SMU00main","LU0444971666.USD","LU0210536198.USD","LU0964807845.USD","EGGY","IE000M9KFDE8.USD","MEDI","SG9999015952.SGD","LU1674673691.USD","LU2552382058.USD","MUD","LU0054578231.USD","SOXQ","LU0820561909.HKD","LU2168564065.EUR","FTXH","IBB","IE00BKDWB100.SGD","SG9999013999.USD","DRMY","IE0002270589.USD","PTF","LU0466842654.USD","LU1861220033.SGD","LU2168563687.JPY","LLYZ","BK4527","LU0820561818.USD","LU2089284900.SGD","CNAV","BK4554","LU0274383776.USD","WLDR","LU2360107168.USD","LU1804176565.USD","SPUU","SG9999001176.USD","SSO","HRTS","LU0109394709.USD","LU0823416689.USD","LU2458330243.SGD","SCHM","LU0203202063.USD","IE00BJJMRX11.SGD","TRFK","SNDU","LU2089984988.USD","LU2417539215.USD","IE00BJLML261.HKD","IE00BFSS7M15.SGD","TBXU","IE00BWXC8680.SGD","HYNX","UDOW","LU2054465674.USD","BK4575","LU0081259029.USD","LU1814569148.SGD","LU2468319806.SGD","LU0882574055.USD","LU2237443549.SGD","IE00B19Z9P08.USD","LU0174119429.USD","LU0162691827.USD","CHPX","SKHU","LU1815336760.USD","SG9999015986.USD","TTXU","LLY","LU0109392836.USD","DMAX","SKHA","LU2746668974.SGD","LU0316494557.USD","LU2168564222.USD","LU2543165471.USD","LU2028103732.USD","LU0417517546.SGD","YSPY","LU0006306889.USD","LU1035775433.USD","BK4599","LU1720051108.HKD","LU2491050154.USD","LU1093756325.SGD","LU2931357623.SGD","FAI","IE00B2B36J28.USD","IE00B19Z3B42.SGD","LU1232071149.USD","SG9999015978.USD","LU0719512351.SGD","LU1823568750.SGD","WUGI","LU0471298777.SGD","CANC","LU0683600562.USD","LU1061106388.HKD","LU1868836591.USD","LU0859254822.USD","LU0354030438.USD","LU1623119135.USD","STX.AU","LU1235294995.USD","LU2111349929.HKD","LU0158827781.USD","SG9999017495.SGD","LU1551013342.USD","LU1366192091.USD","MUYY","SG9999018857.SGD","LU2471134952.CNY","LU0256863902.USD","LU2552382215.SGD","LU2403377893.USD","IE00BK4W5L77.USD","IE0001KFT4U8.USD","SKHYV","LEGR","IXJ","SPYH","FTXL","LU0006061336.USD","IE00BJT1NW94.SGD","LU2089283258.USD","CHPS","LU0094547139.USD","SG9999015945.SGD","LU1917777945.USD","SNDQ","ARTY","WDNA","LU1979441026.SGD",".SPX","SGXZ99366536.SGD","LU2048586759.USD","SOXX","LU1035773651.USD","LU1629891620.HKD","LU0158827948.USD","OPTZ","LU2213496289.HKD","LU1861215975.USD","LU2462591350.SGD","IXN","PSI","LU2360106780.USD","ELIL","VHT","LU1989771016.USD","LU0122379950.USD","LU2361044865.SGD","LU2063271972.USD","LU1983299246.USD","LU2357305700.SGD","LU0203345920.USD","IE00B4R5TH58.HKD","LU0106261372.USD","07709","VOO","LU1069344957.HKD","LU0889565833.HKD","XLK","AIQ","PPH","LU0672654240.SGD","SG9999014898.SGD","LU0345770993.USD","IETC","LU1057294990.SGD","JDOC","SH","SHOC","LU1974910355.USD","IE00BSNM7G36.USD","LU2290526834.HKD","VGT","BK4516","BK4139","LU1267930730.SGD","LU1989764748.USD","IE00B5949003.HKD","LU0882574139.USD","LU2023251221.USD","IE00B4JS1V06.HKD",".IXIC","IE00B7SZLL34.SGD","LU2324357040.USD","LU2602419157.SGD","STX","MIC","SKHY","LU1046421795.USD","LU0096364046.USD","BK4170","SKHX","LU0256863811.USD","LU2750360997.AUD","FCUS","BK4553","LU2102340556.USD","LU2491050071.SGD","SG9999014880.SGD","LU1316542783.SGD","LU0957808578.USD","LU2089985449.USD","LU1983260115.SGD","LU1145028129.USD","SKDD","LU0238689110.USD","ELIS","IHE","LU2237443382.USD","LU1868837136.USD","BK4566","LU2461242641.AUD","USXF","LU2023250330.USD","LU1670628061.USD","LU2264538146.SGD","IE0009356076.USD","LU0689472784.USD","IE0005OL40V9.USD","LU0240878834.USD","LU2237443978.SGD","SPYQ","LU1548497426.USD","LU2471134879.HKD","GB00BDT5M118.USD","ILDR","PJP","LU0320765059.SGD","IE00BJJMRZ35.SGD","BK4505","LU0640476718.USD","LU2361045086.USD","SNDG","LU0476273544.USD","LU1778281490.HKD","SPDN","DXD","SKUU","LU2087625088.SGD","SPXL","LU2237443465.HKD","LLYX","LU0061475181.USD","EFIV","SG9999001424.SGD","CHAT","DISK","LU2168564495.EUR","LU1989764664.SGD","LU1023059063.AUD","SG9999014906.USD","SPXS","BK4581","BK4007","IE0004445239.USD","SMH","LU0823434740.USD","LU1914381329.SGD","IE00B775H168.HKD","LU0058720904.USD","LU0943347566.SGD","LU2750360641.GBP","IE00B1XK9C88.USD","SGXZ51526630.SGD","LU2471134796.USD","QQQA","IE00BJJMRY28.SGD","LU0114720955.EUR","IE0009355771.USD","LU0432979614.USD","MEDX","IE00B19Z3581.USD","IE00BFTCPJ56.SGD","LU2756315664.SGD","LU2237438978.USD","SDS","RXL",".DJI","LU2491049909.HKD","SGXZ31699556.SGD","BAI","UPRO","XNTK","MMAX","LU0642271901.SGD","LU2237443895.HKD","MHIP","LU0323591593.USD","LU0240877869.USD","AIS","FDTX","LU0203201768.USD","LU0234572021.USD","FHLC","SNXX","CURE","LU0082616367.USD","LU1551013425.SGD","LU1280957306.USD","COWG","OZEM","LU0109391861.USD","IE0034235303.USD","SPYM","LU0154236417.USD","IYH","LU1852331112.SGD","SPXU","LU2756315318.SGD","LU0708995401.HKD","LU2471134523.USD","MULL","LU0056508442.USD","LU0889565916.HKD","IE0034235188.USD","LU0792757196.USD","LU0198837287.USD","LU1291159041.SGD","LU1868836914.USD","LU1069347547.HKD","TRUH","LU2360106947.USD","FXL","LU2458330169.SGD","DOG","WDC","LU2211815571.USD","LU2236285917.USD","LU0345770308.USD","LU2357627491.SGD","LU0133085943.USD","BK4543","LU2286300806.USD","LU0097036916.USD","SGXZ57979304.SGD","YMmain","SCHA","QQQG","IE00B19Z9Z06.USD","LU0456855351.SGD","LU0266013472.USD","SKHZ","LU1642822529.SGD","FSMD","SMAX","LU1720051017.SGD","XLV","LU0889566641.SGD","HIBL","LU2265009873.SGD","LU2361044949.HKD","BOBP","BK4512","BK4533","LU0225283273.USD","AIFD","LU2023250504.SGD","LU0079474960.USD","SG9999014914.USD","BK7142","LU2271345857.HKD","LU0072461881.USD","CGGO","IE0004445015.USD","LU0963586101.USD","SDOW","LU2168564149.EUR","LU0786609619.USD","LU2552382132.HKD","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169402008","title":"异动解读｜Argenx SE盘中上涨9.45%，核心药物efgartigimod三期临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1169402008","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169402008?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:30","pubTimestamp":1786973435,"startTime":"0","endTime":"0","summary":"8月17日，Argenx SE盘中上涨9.45%，报931.73美元/股，成交额3068.0万美元。消息面上，公司宣布其药物efgartigimod在针对成人自身免疫性肌炎的三期ALKIVIA临床试验中达到主要终点。该试验也是全球首个在免疫介导性坏死性肌病这一无获批疗法的疾病亚型中取得显著改善的三期临床试验。此前RBC Capital Markets曾指出，肌炎数据是公司股价最大的潜在催化剂。公司二季度产品净销售额达15.16亿美元，同比增长60%，EPS为7.32美元，业绩基本面稳健。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660481020","title":"美股异动 | Argenx(ARGX.US)盘前涨超10% 自身免疫性肌炎药物Vyvgart III期研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2660481020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660481020?lang=zh_cn&edition=full","pubTime":"2026-08-17 18:48","pubTimestamp":1786963699,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BFTCPJ56.SGD","IBB","BK4134","BK4139","BK4588","IE00BJJMRZ35.SGD","ARGX","IE0009355771.USD","LU0889565916.HKD","BK4585","FMED","BK4505","IE00BJT1NW94.SGD","LU2324357040.USD","IE0034235188.USD","IE00B2B36J28.USD","LU0823416689.USD","LU0320765992.SGD","LU1983260115.SGD","IE00B4R5TH58.HKD","TBXU","LU0109394709.USD","IE0002141913.USD","III"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.argenx.com","stockEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":-0.0197},{"period":"3month","weight":0.0382},{"period":"6month","weight":0.1446},{"period":"1year","weight":0.0906},{"period":"ytd","weight":0.0716}],"compareEarnings":[{"period":"1week","weight":-0.0199},{"period":"1month","weight":-0.0199},{"period":"3month","weight":-0.0201},{"period":"6month","weight":0.0311},{"period":"1year","weight":0.1039},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Argenx Se根据荷兰法律于2008年4月25日成立，是一家私人有限责任公司（besloten vennootschap met beperkte aansprakelijkheid）。 于2014年5月28日，根据公证转换契约及修订，该公司转为上市有限责任公司（naamloze vennootschap）。 该公司是一家处于商业阶段的、全球性的、完全整合的生物制药公司，开发用于治疗严重自身免疫性疾病的差异化疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.007923},{"month":2,"riseRate":0.333333,"avgChangeRate":0.026997},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.02217},{"month":4,"riseRate":0.777778,"avgChangeRate":0.0372},{"month":5,"riseRate":0.555556,"avgChangeRate":0.061118},{"month":6,"riseRate":0.8,"avgChangeRate":0.059431},{"month":7,"riseRate":0.6,"avgChangeRate":0.070059},{"month":8,"riseRate":0.7,"avgChangeRate":0.036587},{"month":9,"riseRate":0.4,"avgChangeRate":-0.026985},{"month":10,"riseRate":0.6,"avgChangeRate":0.026471},{"month":11,"riseRate":0.8,"avgChangeRate":0.105661},{"month":12,"riseRate":0.444444,"avgChangeRate":0.116024}],"exchange":"NASDAQ","name":"Argenx SE","nameEN":"Argenx SE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Argenx SE(ARGX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Argenx SE(ARGX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Argenx SE,ARGX,Argenx SE股票,Argenx SE股票老虎,Argenx SE股票老虎国际,Argenx SE行情,Argenx SE股票行情,Argenx SE股价,Argenx SE股市,Argenx SE股票价格,Argenx SE股票交易,Argenx SE股票购买,Argenx SE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Argenx SE(ARGX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Argenx SE(ARGX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}